Table V.

Methods for the prevention of acute ischemic stroke.

Population in question	Current recommendation	Potential drugs for research
General population without risk of COVID-19	Regular physical activity, consumption of sufficient water/liquids, low-fat diet, low-salt diet	None
Asymptomatic patients screened positive for SARS-CoV-2	No prophylaxis, regular physical activity, consumption of sufficient water/liquids, low-fat diet, low-salt diet	DOACs, aspirin, clopidogrel
COVID-19 patients being managed at the outpatient clinic	Individual risk assessment for AIS, regular physical activity, consumption of sufficient water/liquids, low-fat diet, low-salt diet	DOACs, aspirin, clopidogrel
COVID-19 patients admitted to hospital in non-ICU setting	Prophylactic LMWH if not contraindicated, consumption of sufficient water/liquids, low-fat diet, low-salt diet	DOACs, aspirin, clopidogrel, Tpa, tocilizumab, dornase alfa, pirfenidone, tiotropium, colchicine, eculizumab, HrsACE2
Severe COVID-19 patients requiring ICU	Prophylactic LMWH if not contraindicated	Tpa, tocilizumab, dornase alfa, pirfenidone, tiotropium, colchicine, eculizumab, HrsACE2
Discharged COVID-19 patients	Individual risk assessment for AIS, prophylactic anticoagulation for 45 days if not contraindicated, regular physical activity, consumption of sufficient water/liquids, low-fat diet, low-salt diet	DOACs, aspirin, clopidogrel

SARS-CoV-2, acute respiratory syndrome coronavirus 2; DOAC, direct oral anticoagulant; AIS, acute ischemic stroke; LMWH, low molecular weight heparin; Tpa, tissue plasminogen activator; ICU, intensive care unit; HrsACE2, human recombinant soluble angiotensin-converting enzyme 2.